Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30475298 | 0.82 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1GAAALPL | |
| SCHEMBL3051213 | 0.82 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1GAAALPL | |
| SCHEMBL30645638 | 0.79 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL1396210 | 0.79 | ALDH1A1 (0.44) | ALDH1A1KDM4EGAAALPL | |
| SCHEMBL17627048 | 0.79 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL16479224 | 0.76 | ALOX15 (0.51) | ALDH1A1HSD17B10ALPLSMN1; SMN2MAPK1 | |
| SCHEMBL30316663 | 0.75 | ALPL (0.39) | MEN1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL14858215 | 0.74 | CCNA2 (0.42) | ALDH1A1ALPL | |
| SCHEMBL29562157 | 0.73 | RECQL (0.62) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL5026395 | 0.73 | RECQL (0.62) | MEN1KMT2AALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212167-A1 | METHOD FOR SYNTHESIZING ANTI-TUMOR COMPOUND AND INTERMEDIATES THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212167-A1 | METHOD FOR SYNTHESIZING ANTI-TUMOR COMPOUND AND INTERMEDIATES THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-9751865-B2 | Dihydro-hydantoin derivatives with herbicidal activity | SYNGENTA LIMITED (GB) | 2017-09-05 | — | — | US | disclosed |
| US-9605004-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20160375006-A1 | USES OF PARALOG-SELECTIVE INHIBITORS OF GSK3 KINASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-29 | — | — | US | disclosed |
| US-20160318906-A1 | DIHYDRO-HYDANTOIN DERIVATIVES WITH HERBICIDAL ACTIVITY | SYNGENTA LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160168126-A1 | CHEMICAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
| US-20160159819-A1 | CHEMICAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2016-06-09 | — | — | US | disclosed |
| US-9096594-B2 | Kinase inhibitors and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140107141-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2014-04-17 | — | — | US | disclosed |
| US-20100048617-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORP. | 2010-02-25 | — | — | US | disclosed |
| US-20100022486-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-01-28 | — | — | US | disclosed |
| US-20100022486-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-01-28 | — | — | US | disclosed |
| US-20100022486-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-01-28 | — | — | US | disclosed |
| WO-2009056556-A1 | SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009056556-A1 | SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009010560-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS INHIBITORS OF STEAROYL-COA DESATURASE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010560-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS INHIBITORS OF STEAROYL-COA DESATURASE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008074833-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074832-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE ( SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107141-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | GSK3B, GSK3A, CSNK1A1 | MEN1 2029/4885KMT2A 756/4885ALDH1A1 1328/4885 |
| US-20160168126-A1 | CHEMICAL COMPOUNDS | RDX, CBR3, RRS1 | MEN1 3215/4885KMT2A 1822/4885ALDH1A1 326/4885 |
| US-20160318906-A1 | DIHYDRO-HYDANTOIN DERIVATIVES WITH HERBICIDAL ACTIVITY | RDX, DDT, CBR3 | MEN1 3776/4885KMT2A 1259/4885ALDH1A1 96/4885 |
| US-20230212167-A1 | METHOD FOR SYNTHESIZING ANTI-TUMOR COMPOUND AND INTERMEDIATES THEREOF | SQLE, HCCS, DHPS | MEN1 518/4885KMT2A 4045/4885ALDH1A1 1276/4885 |
| US-20160375006-A1 | USES OF PARALOG-SELECTIVE INHIBITORS OF GSK3 KINASES | GSK3B, GSK3A, GSKIP | MEN1 3187/4885KMT2A 732/4885ALDH1A1 3573/4885 |
| US-20160159819-A1 | CHEMICAL COMPOUNDS | RDX, CBR3, RRS1 | MEN1 3279/4885KMT2A 2070/4885ALDH1A1 237/4885 |
| US-20100048617-A1 | COMPOUNDS | SCD, SCD5, CYP11B2 | MEN1 3487/4885KMT2A 3757/4885ALDH1A1 603/4885 |
| US-20100022486-A1 | COMPOUNDS | SCD, CYP11B2, SCD5 | MEN1 3580/4885KMT2A 3791/4885ALDH1A1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.